Method for reducing serum lipoprotein(a) concentration

Patent 5741514 Issued on April 21, 1998. Estimated Expiration Date:

August 31, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Lipid replacement therapy
Patent #: 4812314
Issued on: 03/14/1989
Inventor: Barenholz , et al.

Method for lowering plasma levels of lipoprotein (a) Patent #: 5489611
Issued on: 02/06/1996
Inventor: Lee, et al.

Inventors

Assignee

Yissum Research Development Company of the Hebrew University of Jerusalem

Application

No. 521670 filed on 08/31/1995

US Classes:

424/450Liposomes

Examiners

Primary: Kishore, Gollamudi S.

Attorney, Agent or Firm

Foley & Lardner

International Class

A61K 009/127

Abstract

A method of reducing the serum Lp(a) concentration in a subject is disclosed. A suspension of small, unilamellar vesicles composed primarily of phospholipids, similar in nature to those of egg phosphatidylcholine, is administered parenterally to a subject having or at risk for developing a disease condition associated with an elevated serum Lp(a) concentration. In the method, liposomes are infused over an extended period of time of at least several weeks, until a significant drop in serum Lp(a) concentration is observed.

Other References

"Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein"--1986 Elsev Science Publishers B.V. (Biomedical Division); Williams et al
"Serum Lipoprotein (a) Levels Before and After Subtotal Thyroidectomy in Subjects With Hyperthyroidism"--Metabolism, vol. 44, No. 1 (Jan.), 1995: pp. 4-7; Yamamoto et al
"The Relationship Between Serum Lipoprotein(a) and Restenosis After Initial Elective Percutaneous Transluminal Coronary Angioplasty"--Japanese Circulation Journal--vol. 57, Aug. 1993; Tenda et al
"Perspectives in Biology and Medicine"--Perspectives in Biology and Medicine, 27, 3--Spring 1984; Williams et al
"Low Levels of Serum Apolipoprotein A I and A II in Senile Dementia"--The Japanese Journal of Psychiatry and Neurology, vol. 48 No. 3, 1994; Kuriyama et al
"Increased Concentrations of Serum Lp(a) Lipoprotein in Patients With Primary Gout"--Annals of the Rheumatic Diseases 1995; 54: 90-93; Takahashi et al
"Elevated Serum Lp(a) Levels in the Early and Advanced Stages of Breast Cancer"--Cancer Biochem, Biophys., 1994, vol. 14, pp. 133-136; Kokoglu et al
"Lipoprotein(a) in Type 1 Diabetic Patients with Renal Disease"--Original Articles--May 11, 1994; Groop et al
"Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty by Reducing Lipoprotein (a) Levels with Low-Density Lipoprotein Apheresis"--Jun. 1, 1994, vol. 73, No. 15; Daida et al
Elevated Serum Lipoprotein(a) is a Risk Factor for Clinical Recurrence After Coronary Balloon Angioplasty--Circulation vol. 91, No. 5, Mar. 1, 1995; Desmarais et al.; Desmarais et a